Pharmacist Digest

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

p applicant Horizon

Solving the taxing problems of taxanes?

European Pharmaceutical Review

NOVEMBER 4, 2022

Oraxol is a two-component therapy consisting of an oral formulation of paclitaxel, administered in combination with encequidar, a proprietary ‘booster’ which inhibits P-gp to improve absorption and consequent systemic exposure to paclitaxel. Modra Pharmaceuticals is developing ModraDoc006/r, which, like Oraxol, is a two?component

Chemotherapy

Chemotherapy Hospitals Packaging

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results for GA

pharmaphorum

NOVEMBER 16, 2022

And yet, the OAKS study, as well as the DERBY study, has illuminated possible hope on the horizon. All of these statistical comparisons are nominal, but the nominal p-values were highly significant at 0.003 or less.”. It will be interesting to see what the outcome of that application is. Bleak prospects, indeed.

Immunity

Immunity Immunization Hospitals Drug Development

Solving the taxing problems of taxanes?

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results for GA

Stay Connected